Beskrivning
This product is a hot-start DNA polymerase that utilizes two proprietary antibodies for dual blocking. It effectively inhibits both the 5'→3' polymerase activity and the 5'→3' exonuclease activity of Taq DNA polymerase. Upon heating at the pre-denaturation temperature for 30 seconds, the blocking antibodies are completely inactivated, releasing both the DNA polymerase and exonuclease activities.
This dual-blocking feature offers a dual advantage: it not only prevents non-specific amplification caused by mismatches or primer-dimers but also inhibits the degradation of probes that can lead to a decrease in fluorescent signal. This dual protection ensures greater stability of in vitro diagnostic reagents during transportation or when used at room temperature.
Features
- Antibody-mediated hot start: Activated by a brief 95 °C incubation (30–60 s) for precise reaction control.
- High sensitivity & specificity: Reliable target detection with minimal non-specific amplification.
- Inhibitor tolerant: Performs well in the presence of common inhibitors from blood, swabs, and residual prep reagents (e.g., phenol, alcohol).
|
Components No. |
Name |
14325ES76 (1,000 U) |
14325ES80 (10,000 U) |
14325ES92 (25,000 U) |
14325ES93 (100,000 U) |
|
14325 |
Robust Hotstart Taq (20 U/μL) |
50 μL |
500 μL |
1.25 mL |
5 mL |
Components
Storage
This product should be stored at -25~-15℃ for 2 years.
Figure
1. Direct Amplification from Swab Samples
Nasopharyngeal swabs were vortexed in a direct lysis buffer or diluted in TE buffer to prepare templates at equivalent concentrations. Both were tested using the 14325 qPCR master mix and a leading commercial alternative. Results showed that the 14325 formulation exhibits superior inhibitor tolerance, enabling reliable direct amplification from swab samples without purification.
Figure 1. Comparison of direct swab amplification performance: 14325 vs. commercial reagents.
2. Direct Amplification from Plasma Samples
Clinical plasma samples were diluted in either plasma itself or TE buffer to match template concentrations. When tested with the 14325 qPCR mix and a commercial reagent, the 14325 system demonstrated significantly better resistance to inhibitors—supporting direct amplification with up to 30% final plasma concentration.
Figure 2. Comparison of direct plasma amplification performance: 14325 vs. commercial reagent.
Documents:
Safety Data Sheet
Manuals
14325_Manual_Ver.EN20260304.pdf
Betalning och säkerhet
Din betalningsinformation behandlas säkert. Vi lagrar inte kreditkortsuppgifter och har inte heller tillgång till din kreditkortsinformation.
Du kanske också gillar
Förfrågan
Vanliga frågor
Produkten är endast avsedd för forskningsändamål och är inte avsedd för terapeutisk eller diagnostisk användning hos människor eller djur. Produkter och innehåll skyddas av patent, varumärken och upphovsrätt som ägs av Yeasen Biotechnology. Varumärkessymboler anger ursprungsland, inte nödvändigtvis registrering i alla regioner.
Vissa applikationer kan kräva ytterligare immateriella rättigheter från tredje part.
Yeasen är dedikerad till etisk vetenskap, och anser att vår forskning bör behandla kritiska frågor samtidigt som den säkerställer säkerhet och etiska standarder.